Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Crizotinib, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

NCT00939770 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00939770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00939770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Crizotinib, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Lead sponsor
Children's Oncology Group
Phase
Phase 1/2
Overall status
Completed
Start date
September 21, 2009
Completion date
December 31, 2018
Enrollment
122 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent childhood anaplastic large cell lymphoma, recurrent malignant solid neoplasm, recurrent neuroblastoma, refractory anaplastic large cell lymphoma, refractory malignant solid neoplasm, refractory neuroblastoma